Hartington Business S.L. is founded in Spain.
Work is started on a compound to cure rhinosinusitis.
Iveriapharma is founded in Georgia, enabling the clinical trials for Sinuforte® to start.
Construction of new production plant in Georgia is completed, equipped with the latest production lines and the most advanced manufacturing resources. Investigation into the treatment of herpes is initiated.
Introduction of Nasodren® (Sinuforte®) in Georgia, Azerbaijan, Ukraine, Kazakhstan and Belarus.
Favourable results from the preclinical trials; clinical trials on the treatment of herpes are initiated.
Hartington Pharmaceutical S.L. is founded in Spain.
Launch of Sinuforte® in Russia.
Hartington enters the Western European pharmaceutical market with the Spanish Licence for Fluirespira Forte® from Zambon Group.
Enters the pharmaceutical market of the following countries: Germany, Poland, and Slovenia. Hartington Pharma Ltd is set up for the manufacture of Nasodren®.
Important documents released such as US clinical trial (434-083) conclusion, Nasodren® monograph, newsletter, consumer focus, Nasodren® web page, sales folder. Expansion of Nasodren® to new countries such as Greece, Romania and Bulgaria.
Introduction of Nasodren® in more new markets: the Netherlands, Luxemburg, Czech Republic, Baltic countries and Austria. Introduction of the consumer corporate campaign.
Launch of Nasodren® in Australia and Arabia Saudi.
Introduction of Nasodren® in Belgium, France, Switzerland, Sweden and Croatia.
Launch of Nasodren® in Serbia and Finland.
Launch of Nasodren® in Turkmenistan and Spain.